Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$40.40
+2.4%
$41.80
$31.01
$50.21
$20.52B0.623.68 million shs3.22 million shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$233.88
-0.1%
$239.81
$229.40
$287.32
$67.57B0.431.40 million shs766,256 shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$68.02
+1.0%
$67.31
$48.35
$69.21
$99.79B0.786.39 million shs7.65 million shs
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$7.40
+1.4%
$6.91
$6.33
$8.38
$16.31B1.1282,338 shs165,275 shs
Stryker Co. stock logo
SYK
Stryker
$327.68
+0.7%
$349.74
$249.98
$361.41
$123.82B0.89998,804 shs1.69 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
+2.36%+0.90%-3.67%+5.17%-10.80%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-0.10%-0.36%-5.02%-1.85%-10.46%
Boston Scientific Co. stock logo
BSX
Boston Scientific
+1.02%+0.86%+0.59%+12.21%+33.09%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
+1.37%+8.35%+10.45%+5.41%+5.26%
Stryker Co. stock logo
SYK
Stryker
+0.69%-3.38%-7.07%+4.97%+7.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.927 of 5 stars
3.15.02.54.03.31.72.5
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.7612 of 5 stars
2.43.03.34.03.22.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.3306 of 5 stars
2.53.00.04.22.52.52.5
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
4.7803 of 5 stars
2.43.03.34.23.22.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.22
Hold$46.3014.60% Upside
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0019.72% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.00
Buy$68.500.71% Upside
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
2.50
Moderate BuyN/AN/A
Stryker Co. stock logo
SYK
Stryker
2.77
Moderate Buy$340.673.96% Upside

Current Analyst Ratings

Latest BSX, BDX, BAX, SYK, and FSNUY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $78.00
4/15/2024
Stryker Co. stock logo
SYK
Stryker
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$360.00 ➝ $386.00
4/11/2024
Stryker Co. stock logo
SYK
Stryker
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$365.00 ➝ $400.00
4/4/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$68.00 ➝ $72.00
4/4/2024
Stryker Co. stock logo
SYK
Stryker
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$340.00 ➝ $370.00
4/3/2024
Baxter International Inc. stock logo
BAX
Baxter International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$41.00 ➝ $44.00
4/3/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$71.00 ➝ $79.00
4/3/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$69.00 ➝ $80.00
4/3/2024
Stryker Co. stock logo
SYK
Stryker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$362.00 ➝ $406.00
3/7/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$65.00 ➝ $77.00
3/5/2024
Baxter International Inc. stock logo
BAX
Baxter International
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$42.00 ➝ $45.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$14.81B1.39$5.37 per share7.53$16.69 per share2.42
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.49$20.20 per share11.58$88.92 per share2.63
Boston Scientific Co. stock logo
BSX
Boston Scientific
$14.24B7.01$2.93 per share23.19$13.33 per share5.10
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$24.01B0.69$2.23 per share3.32$15.07 per share0.49
Stryker Co. stock logo
SYK
Stryker
$20.50B6.08$13.50 per share24.27$48.94 per share6.70

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
$2.66B$5.227.7412.632.1217.77%19.49%4.77%5/2/2024 (Confirmed)
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2255.4216.331.936.44%13.57%6.56%5/2/2024 (Confirmed)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.59B$1.0763.5726.782.3611.19%15.99%8.87%4/24/2024 (Confirmed)
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
-$639.61M$0.1167.287.25N/A0.71%4.88%2.02%N/A
Stryker Co. stock logo
SYK
Stryker
$3.17B$8.2539.7224.752.6215.44%22.99%10.69%4/30/2024 (Confirmed)

Latest BSX, BDX, BAX, SYK, and FSNUY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Baxter International Inc. stock logo
BAX
Baxter International
$0.61N/A-$0.61N/AN/AN/A  
5/2/2024N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.96N/A-$2.96N/AN/AN/A  
4/30/2024N/A
Stryker Co. stock logo
SYK
Stryker
$2.35N/A-$2.35N/AN/AN/A  
4/24/2024N/A
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.51$0.51N/AN/AN/AN/A  
2/8/2024Q4 2023
Baxter International Inc. stock logo
BAX
Baxter International
$0.86$0.88+$0.02$1.28$3.81 billion$3.89 billion    
2/1/2024Q1 2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.39$2.68+$0.29$4.40$4.73 billion$4.71 billion      
1/31/2024Q4 23
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.51$0.55+$0.04$0.76$3.59 billion$3.73 billion    
1/30/2024Q4 23
Stryker Co. stock logo
SYK
Stryker
$3.27$3.46+$0.19$3.94$5.60 billion$5.82 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$1.162.87%+6.70%22.22%N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.62%+4.77%90.05%52 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.172.30%N/A154.56%N/A
Stryker Co. stock logo
SYK
Stryker
$3.200.98%+9.00%38.79%31 Years

Latest BSX, BDX, BAX, SYK, and FSNUY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2024
Stryker Co. stock logo
SYK
Stryker
Quarterly$0.800.93%3/27/20243/29/20244/30/2024
2/12/2024
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.292.88%2/29/20243/1/20244/1/2024
1/23/2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$0.951.59%3/7/20243/8/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.31
1.48
1.04
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.44
1.32
0.82
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
0.36
1.54
1.44
Stryker Co. stock logo
SYK
Stryker
0.59
1.58
0.97

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
60,000507.83 million506.71 millionOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
48,0001.47 billion1.46 billionOptionable
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
316,9202.23 billionN/ANot Optionable
Stryker Co. stock logo
SYK
Stryker
52,000380.47 million359.54 millionOptionable

BSX, BDX, BAX, SYK, and FSNUY Headlines

SourceHeadline
Stryker (SYK) Set to Announce Quarterly Earnings on TuesdayStryker (SYK) Set to Announce Quarterly Earnings on Tuesday
americanbankingnews.com - April 23 at 3:28 AM
Stryker Co. (NYSE:SYK) Receives Consensus Rating of "Moderate Buy" from AnalystsStryker Co. (NYSE:SYK) Receives Consensus Rating of "Moderate Buy" from Analysts
americanbankingnews.com - April 23 at 2:18 AM
Stryker (SYK) to Release Quarterly Earnings on TuesdayStryker (SYK) to Release Quarterly Earnings on Tuesday
marketbeat.com - April 23 at 2:18 AM
Stryker Co. (NYSE:SYK) Given Consensus Rating of "Moderate Buy" by AnalystsStryker Co. (NYSE:SYK) Given Consensus Rating of "Moderate Buy" by Analysts
marketbeat.com - April 23 at 2:13 AM
Stryker Co. (NYSE:SYK) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MAStryker Co. (NYSE:SYK) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA
marketbeat.com - April 22 at 11:30 PM
Stryker launches next-gen AEDStryker launches next-gen AED
massdevice.com - April 22 at 3:30 PM
Hosopple to return as Stryker football coachHosopple to return as Stryker football coach
bryantimes.com - April 21 at 11:42 PM
Stryker High School Celebrates Disco Prom NightStryker High School Celebrates Disco Prom Night
thevillagereporter.com - April 21 at 11:42 PM
Calamos Wealth Management LLC Sells 3,307 Shares of Stryker Co. (NYSE:SYK)Calamos Wealth Management LLC Sells 3,307 Shares of Stryker Co. (NYSE:SYK)
marketbeat.com - April 21 at 9:58 AM
Greenleaf Trust Cuts Holdings in Stryker Co. (NYSE:SYK)Greenleaf Trust Cuts Holdings in Stryker Co. (NYSE:SYK)
marketbeat.com - April 19 at 8:42 PM
Stryker Unusual Options Activity For April 19Stryker Unusual Options Activity For April 19
benzinga.com - April 19 at 6:15 PM
How the US Army botched a $1 billion upgrade of the Stryker armored vehicles gunHow the US Army botched a $1 billion upgrade of the Stryker armored vehicle's gun
msn.com - April 19 at 1:33 AM
Stryker Co. (NYSE:SYK) Holdings Increased by Daiwa Securities Group Inc.Stryker Co. (NYSE:SYK) Holdings Increased by Daiwa Securities Group Inc.
marketbeat.com - April 18 at 9:59 AM
3 Robotics Stocks to Turn $1000 into $1 Million: April 20243 Robotics Stocks to Turn $1000 into $1 Million: April 2024
investorplace.com - April 18 at 9:35 AM
Flossbach Von Storch AG Reduces Stock Position in Stryker Co. (NYSE:SYK)Flossbach Von Storch AG Reduces Stock Position in Stryker Co. (NYSE:SYK)
marketbeat.com - April 17 at 10:12 PM
Stryker (NYSE:SYK) vs. Valeritas (OTCMKTS:VLRXQ) Critical ReviewStryker (NYSE:SYK) vs. Valeritas (OTCMKTS:VLRXQ) Critical Review
americanbankingnews.com - April 17 at 1:46 AM
Lady Birds overcome 10 errors, hold off StrykerLady Birds overcome 10 errors, hold off Stryker
northwestsignal.net - April 17 at 1:27 AM
Stryker nabs first win of season; Montpelier scores 33Stryker nabs first win of season; Montpelier scores 33
northwestsignal.net - April 17 at 1:27 AM
HealthInvest Partners AB Takes Position in Stryker Co. (NYSE:SYK)HealthInvest Partners AB Takes Position in Stryker Co. (NYSE:SYK)
marketbeat.com - April 16 at 6:49 PM
Orthofix names former Stryker exec as chief legal officerOrthofix names former Stryker exec as chief legal officer
beckersspine.com - April 16 at 3:26 PM
Institutional investors in Stryker Corporation (NYSE:SYK) lost 3.0% last week but have reaped the benefits of longer-term growthInstitutional investors in Stryker Corporation (NYSE:SYK) lost 3.0% last week but have reaped the benefits of longer-term growth
finance.yahoo.com - April 16 at 10:26 AM
Stryker (NYSE:SYK) Price Target Increased to $386.00 by Analysts at Royal Bank of CanadaStryker (NYSE:SYK) Price Target Increased to $386.00 by Analysts at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Historic Reflection: Stryker 2005 – Strydel, Inc.Historic Reflection: Stryker 2005 – Strydel, Inc.
thevillagereporter.com - April 15 at 10:46 PM
Royal Bank of Canada Increases Stryker (NYSE:SYK) Price Target to $386.00Royal Bank of Canada Increases Stryker (NYSE:SYK) Price Target to $386.00
marketbeat.com - April 15 at 3:31 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Baxter International logo

Baxter International

NYSE:BAX
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Boston Scientific logo

Boston Scientific

NYSE:BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA

OTCMKTS:FSNUY
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Stryker logo

Stryker

NYSE:SYK
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.